Vor Biopharma Inc. VOR
We take great care to ensure that the data presented and summarized in this overview for Vor Biopharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VOR
View allLatest Institutional Activity in VOR
Top Purchases
Top Sells
About VOR
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2025
|
Sandesh Mahatme CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
694,137
-100.0%
|
-
|
|
Oct 30
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
24,579
-3.06%
|
$614,475
$25.12 P/Share
|
|
Oct 29
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
251,518
-23.82%
|
$6,287,950
$25.22 P/Share
|
|
Oct 28
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
124,311
-5.39%
|
$3,356,397
$27.64 P/Share
|
|
Oct 27
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
90,941
-7.16%
|
$2,546,348
$28.12 P/Share
|
|
Oct 24
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
53,345
-4.03%
|
$1,493,660
$28.01 P/Share
|
|
Oct 23
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
76,880
-5.49%
|
$2,152,640
$28.01 P/Share
|
|
Oct 21
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
25,027
-1.75%
|
$700,756
$28.11 P/Share
|
|
Oct 21
2025
|
Reprogrammed Interchange LLC |
SELL
Open market or private sale
|
Direct |
200
-0.02%
|
$6,000
$30.07 P/Share
|
|
Oct 20
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
92,023
-49.15%
|
$2,668,667
$29.88 P/Share
|
|
Oct 20
2025
|
Reprogrammed Interchange LLC |
SELL
Open market or private sale
|
Direct |
11,616
-0.99%
|
$348,480
$30.05 P/Share
|
|
Oct 17
2025
|
Reprogrammed Interchange LLC |
SELL
Open market or private sale
|
Direct |
25,717
-1.07%
|
$771,510
$30.61 P/Share
|
|
Oct 17
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
260,859
-18.65%
|
$7,825,770
$30.13 P/Share
|
|
Oct 16
2025
|
Reprogrammed Interchange LLC |
SELL
Open market or private sale
|
Direct |
2,021
-0.17%
|
$60,630
$30.45 P/Share
|
|
Oct 16
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
151,803
-6.39%
|
$4,554,090
$30.34 P/Share
|
|
Oct 15
2025
|
Reprogrammed Interchange LLC |
SELL
Open market or private sale
|
Direct |
71,655
-1.89%
|
$2,221,305
$31.96 P/Share
|
|
Oct 15
2025
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
51,363
-2.88%
|
$1,540,890
$30.86 P/Share
|
|
Oct 14
2025
|
Reprogrammed Interchange LLC |
SELL
Open market or private sale
|
Direct |
33,668
-2.57%
|
$1,010,040
$30.32 P/Share
|
|
Oct 13
2025
|
Reprogrammed Interchange LLC |
SELL
Open market or private sale
|
Direct |
22,006
-0.83%
|
$704,192
$32.73 P/Share
|
|
Oct 10
2025
|
Reprogrammed Interchange LLC |
SELL
Open market or private sale
|
Direct |
40,983
-2.98%
|
$1,229,490
$30.97 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 32M shares |
|---|---|
| Open market or private purchase | 39M shares |
| Open market or private sale | 7.88M shares |
|---|---|
| Payment of exercise price or tax liability | 23.3K shares |
| Sale (or disposition) back to the issuer | 694K shares |